Entrada Therapeutics, Inc. Share Price
NASDAQ: TRDA | Micro CapEntrada Therapeutics, Inc. Stock Performance
Open $7.03 | Prev. Close $6.87 | Circuit Range N/A |
Day Range $6.76 - $7.03 | Year Range $4.94 - $16.43 | Volume 27,864 |
Average Traded $6.85 |
Entrada Therapeutics, Inc. Share Price Today
As of 10 August 2026, Entrada Therapeutics, Inc.'s share price is $6.86. The stock opened at $7.03, compared to its previous close of $6.87. During today's trading session, Entrada Therapeutics, Inc.'s share price traded between $6.76 and $7.03, with an average price of $6.89. Over the past 52 weeks, the stock has recorded a high of $16.43 and a low of $4.94. In terms of performance, Entrada Therapeutics, Inc.'s share price has declined by 42.55% over the last six months and is up 25.41% on a year-on-year basis.
Entrada Therapeutics, Inc. Share Price Chart
Entrada Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $283.81M | PE Ratio (TTM) -1.98 | Dividend Yield N/A |
EPS (TTM) $-3.47 | Revenue (TTM) $25.42M | Return On Equity (TTM) -46.96% |
Profit Margin -565.48% | Debt to Equity 0.08 | Quarterly Earnings Growth YoY -214.52% |
Entrada Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Entrada Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Entrada Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $6.77 | $6.88 | +1.18% |
Jul 2026 | $7.42 | $6.80 | -7.73% |
Jun 2026 | $6.98 | $7.37 | +4.54% |
May 2026 | $13.36 | $7.05 | -47.78% |
Apr 2026 | $13.10 | $13.50 | +6.85% |
Mar 2026 | $11.61 | $12.63 | +5.82% |
Feb 2026 | $11.44 | $11.94 | +4.51% |
Jan 2026 | $10.29 | $11.43 | +11.14% |
Dec 2025 | $10.16 | $10.28 | +0.15% |
Nov 2025 | $6.76 | $10.27 | +47.59% |
Oct 2025 | $5.83 | $6.96 | +20.33% |
Sep 2025 | $5.44 | $5.78 | +5.67% |
TRDA Share Price FAQs
What is Entrada Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Entrada Therapeutics, Inc. stock?
What is TRDA's market capitalisation today?
What is TRDA's net income for the last quarter?
What is the 5 year returns of TRDA?
What is the high & low stock price of TRDA today?
Can I buy TRDA shares in India?